Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1977 Jan;27(1):111–117.

Cell-mediated immunity in amyloidosis secondary to lepromatous leprosy.

E M Anders, K P McAdam, R F Anders
PMCID: PMC1540912  PMID: 849644

Abstract

Cell-mediated immunity in lepromatous leprosy patients with and without amyloidosis has been studied. Amyloidosis occurred mostly in patients with a history of recurrent erythema nodosum leprosum (ENL) reactions. For this reason, two control groups of leprosy patients were included, one having a history of recurrent ENL and the other little or no ENL. The lack of responsiveness to lepromin in vivo and in vitro, characteristic of lepromatous leprosy, was not altered by the presence of amyloidosis or a history of ENL. No significant difference between the patient groups was observed in the response to PPD in vitro, but skin reactivity to PPD was significantly lower in the patients with amyloidosis than in those without amyloidosis. In contrast, the PHA responses of patients with amyloidosis were significantly higher than those of control patients without a history of ENL, but not significantly different from those of control patients with a history of recurrent ENL. Lepromatous leprosy patients who develop amyloidosis thus appear to belong to a group, susceptible to repeated attacks of ENL, whose PHA responses are higher than those of other lepromatous leprosy patients. The lower skin reactivity to PPD observed in the amyloid group may reflect a general impairment in delayed cutaneous hypersensitivity.

Full text

PDF
111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balina L. M., Fliess E. L., Bachmann A., Cardama J. E., Gatti J. C. Similar alteractions of lymphoblastic dedifferentiation in lepromatous leprosy patients and their healthy lepromin-negative consanguineous offspring. Int J Lepr Other Mycobact Dis. 1973 Jan-Mar;41(1):7–13. [PubMed] [Google Scholar]
  2. Benditt E. P., Eriksen N., Hermodson M. A., Ericsson L. H. The major proteins of human and monkey amyloid substance: Common properties including unusual N-terminal amino acid sequences. FEBS Lett. 1971 Dec 1;19(2):169–173. doi: 10.1016/0014-5793(71)80506-9. [DOI] [PubMed] [Google Scholar]
  3. Briccetti A. B., Cathcart E. S., Cohen A. S. Casein-induced experimental amyloidosis. 2. Lymphocyte transformation in preamyloidotic and amyloidotic guinea pigs. Acta Pathol Microbiol Scand Suppl. 1972;233:162–166. [PubMed] [Google Scholar]
  4. Briccetti A. B., Cathcart E. S., Cohen A. S. Lymphocyte transformation and amyloidosis. An immunologic study of 14 patients with biopsy-proved disease. Int Arch Allergy Appl Immunol. 1973;44(3):349–357. [PubMed] [Google Scholar]
  5. Bullock W. E., Jr, Fasal P. Studies of immune mechanisms in leprosy. 3. The role of cellular and humoral factors in impairment of the in vitro immune response. J Immunol. 1971 Apr;106(4):888–899. [PubMed] [Google Scholar]
  6. Cathcart E. S., Mullarkey M., Cohen A. S. Amyloidosis: an expression of immunological tolerance? Lancet. 1970 Sep 26;2(7674):639–640. doi: 10.1016/s0140-6736(70)91403-0. [DOI] [PubMed] [Google Scholar]
  7. Dierks R. E., Shepard C. C. Effect of phytohemagglutinin and various mycobacterial antigens on lymphocyte cultures from leprosy patients. Proc Soc Exp Biol Med. 1968 Feb;127(2):391–395. doi: 10.3181/00379727-127-32698. [DOI] [PubMed] [Google Scholar]
  8. Druet R. L., Janigan D. T. Experimental amyloidosis. Amyloid induction with a soluble protein antigen in intact, bursectomized and thymectomized chickens. Am J Pathol. 1966 Dec;49(6):1103–1123. [PMC free article] [PubMed] [Google Scholar]
  9. Dwyer J. M., Bullock W. E., Fields J. P. Disturbance of the blood T:B lymphocyte ratio in lepromatous leprosy. Clinical and immunologic correlations. N Engl J Med. 1973 May 17;288(20):1036–1039. doi: 10.1056/NEJM197305172882002. [DOI] [PubMed] [Google Scholar]
  10. Glenner G. G., Terry W., Harada M., Isersky C., Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science. 1971 Jun 11;172(3988):1150–1151. doi: 10.1126/science.172.3988.1150. [DOI] [PubMed] [Google Scholar]
  11. Hardt F., Claësson M. H. Graft-versus-host reactions mediated by spleen cells from amyloidotic and nonamyloidotic mice. Transplantation. 1971 Jul;12(1):36–39. doi: 10.1097/00007890-197107000-00005. [DOI] [PubMed] [Google Scholar]
  12. Husby G., Sletten K., Michaelsen T. E., Natvig J. B. Antigenic and chemical characterization of non-immunoglobulin amyloid proteins. Scand J Immunol. 1972;1(4):393–400. doi: 10.1111/j.1365-3083.1972.tb03305.x. [DOI] [PubMed] [Google Scholar]
  13. Lehner T., Cameron J. S., Ward R. G. Lymphocyte transformation in patients with amyloidosis. Clin Exp Immunol. 1970 Mar;6(3):439–444. [PMC free article] [PubMed] [Google Scholar]
  14. Levin M., Franklin E. C., Frangione B., Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest. 1972 Oct;51(10):2773–2776. doi: 10.1172/JCI107098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lim S. D., Kiszkiss D. F., Jacobson R. R., Choi Y. S., Good R. A. Thymus-dependent lymphocytes of peripheral blood in leprosy patients. Infect Immun. 1974 Feb;9(2):394–399. doi: 10.1128/iai.9.2.394-399.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McAdam K. P., Anders R. F., Smith S. R., Russell D. A., Price M. A. Association of amyloidosis with erythema nodosum leprosum reactions and recurrent neutrophil leucocytosis in leprosy. Lancet. 1975 Sep 27;2(7935):572–573. doi: 10.1016/s0140-6736(75)90168-3. [DOI] [PubMed] [Google Scholar]
  17. Mehra V. L., Talwar G. P., Balakrishnan K., Bhutani L. K. Influence of chemotherapy and serum factors on the mitogenic response of peripheral leucocytes of leprosy patients to phytohaemagglutinin. Clin Exp Immunol. 1972 Oct;12(2):205–213. [PMC free article] [PubMed] [Google Scholar]
  18. Muckle T. J. Impaired immunity in the etiology of amyloidosis: a speculative review. Isr J Med Sci. 1968 Sep-Oct;4(5):1020–1034. [PubMed] [Google Scholar]
  20. RIDLEY D. S. A bacteriologic study of erythema nodosum leprosum. Int J Lepr. 1960 Jul-Sep;28:254–266. [PubMed] [Google Scholar]
  21. Ranlov P., Jensen E. Homograft reaction in amyloidotic mice. Acta Pathol Microbiol Scand. 1966;67(2):161–164. doi: 10.1111/apm.1966.67.2.161. [DOI] [PubMed] [Google Scholar]
  22. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  23. Rosenthal C. J., Franklin E. C. Variation with age and disease of an amyloid A protein-related serum component. J Clin Invest. 1975 Apr;55(4):746–753. doi: 10.1172/JCI107985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. SHUTTLEWORTH J. S., SISTER HILARY ROSS Secondary amyloidosis in leprosy. Ann Intern Med. 1956 Jul;45(1):23–38. doi: 10.7326/0003-4819-45-1-23. [DOI] [PubMed] [Google Scholar]
  25. Scheinberg M. A., Cathcart E. S. Casein-induced experimental amyloidosis. III. Response to mitogens, allogeneic cells, and graft-versus-host reactions in the murine model. Immunology. 1974 Nov;27(5):953–963. [PMC free article] [PubMed] [Google Scholar]
  26. Scheinberg M. A., Cathcart E. S. Comprehensive study of humoral and cellular immune abnormalities in 26 patients with systemic amyloidosis. Arthritis Rheum. 1976 Mar-Apr;19(2):173–182. doi: 10.1002/art.1780190208. [DOI] [PubMed] [Google Scholar]
  27. Sheagren J. N., Block J. B., Trautman J. R., Wolff S. M. Immunologic reactivity in patients with leprosy. Ann Intern Med. 1969 Feb;70(2):295–302. doi: 10.7326/0003-4819-70-2-295. [DOI] [PubMed] [Google Scholar]
  28. Sher R., Holm G., Kok S. H., Koornhof H. J., Glover A. T and CR+ lymphocyte profile in leprosy and the effect of treatment. Infect Immun. 1976 Jan;13(1):31–35. doi: 10.1128/iai.13.1.31-35.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Turk J. L., Waters M. F. Immunological significance of changes in lymph nodes across the leprosy spectrum. Clin Exp Immunol. 1971 Mar;8(3):363–376. [PMC free article] [PubMed] [Google Scholar]
  30. Ulrich M., de Salas B., Convit J. Lymphocyte transformation with phytomitogens in leprosy. Int J Lepr Other Mycobact Dis. 1972 Jan-Mar;40(1):4–9. [PubMed] [Google Scholar]
  31. WILLIAMS R. C., Jr, CATHCART E. S., CALKINS E., FITE G. L., RUBIO J. B., COHEN A. S. SECONDARY AMYLOIDOSIS IN LEPROMATOUS LEPROSY. POSSIBLE RELATIONSHIPS OF DIET AND ENVIRONMENT. Ann Intern Med. 1965 May;62:1000–1007. doi: 10.7326/0003-4819-62-5-1000. [DOI] [PubMed] [Google Scholar]
  32. Waldorf D. S., Sheagren J. N., Trautman J. R., Block J. B. Impaired delayed hypersensitivity in patients with lepromatous leprosy. Lancet. 1966 Oct 8;2(7467):773–776. doi: 10.1016/s0140-6736(66)90366-7. [DOI] [PubMed] [Google Scholar]
  33. Wemambu S. N., Turk J. L., Waters M. F., Rees R. J. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet. 1969 Nov 1;2(7627):933–935. doi: 10.1016/s0140-6736(69)90592-3. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES